February 23, 2023

BullFrog AI Partners with J. Craig Venter Institute to Develop Colorectal Cancer Therapeutic

Collaboration seeks to develop an oncolytic virus that incorporates a novel, precision-targeted approach to improve safety and efficacy

GAITHERSBURG, MD / ACCESSWIRE / February 23, 2023 / BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a co-development arrangement with the J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation, for the design and validation of a synthetic HSV-1 (herpes simplex type 1) virus particle targeting colorectal cancer.

"This project leverages our bfLEAP™ artificial intelligence and machine learning platform to optimize oncolytic HSV-1 particle design for cancer-cell-specific targeting, reduced toxicity, and therapeutic payload," said BullFrog AI's founder and CEO, Vin Singh. "Our objective with this collaboration is to generate a novel class of targeted colorectal cancer therapeutics with potential for a best-in-class toxicity profile, while providing a clear demonstration of our ability to advance development of new medicines using artificial intelligence."

"The JCVI has been at the forefront of synthetic biology for more than 25 years, and we've long stated that the knowledge, tools, and techniques developed have broad use. It is gratifying seeing their application in such an impactful area of human health, and we look forward to working with BullFrog AI," remarked J. Craig Venter, Ph.D., chairman, CEO, and founder of JCVI.

"We are excited to partner with Bullfrog AI. The combination of artificial intelligence and engineered biology approaches has the potential to rapidly develop safer precision cancer therapeutics," added Sanjay Vashee, Ph.D., professor and director of the JCVI, Rockville, Maryland campus.

According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S., excluding skin cancers, and is the third leading cause of cancer-related deaths in the U.S.

About BullFrog AI

BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several

critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.

For more information visit BullFrogAI at

Website: www.bullfrogai.com

LinkedIn: https://www.linkedin.com/company/bullfrogai/

About J. Craig Venter Institute

The J. Craig Venter Institute (JCVI) is a not-for-profit research institute in Rockville, Maryland and La Jolla, California. dedicated to the advancement of the science of genomics; the understanding of its implications for society; and communication of those results to the scientific community, the public, and policymakers. Founded by J. Craig Venter, Ph.D., the JCVI is home to approximately 100 scientists and staff with expertise in human and evolutionary biology, genetics, bioinformatics/informatics, information technology, high-throughput DNA sequencing, genomic and environmental policy research, and public education in science and science policy. The JCVI is a 501(c)(3) organization. For additional information, please visit www.JCVI.org.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Media Contacts:

Bullfrog AI

Todd McKnight
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447

J. Craig Venter Institute

Matthew LaPointe
mlapointe@jcvi.org
301-795-7918

SOURCE: BullFrog AI Holdings, Inc.

View source version on accesswire.com:
https://www.accesswire.com/740483/BullFrog-AI-Partners-with-J-Craig-Venter-Institute-to-Develop-Colorectal-Cancer-Therapeutic